SCHEDULE: Fusion Summer Acquires 17% Stake in Helius Medical

Fusion Summer Limited, controlled by Executive Chairman CHEE Choon Wee, acquired 17.0% of Helius Medical Technologies' Class A Common Stock for approximately $47.0 million.

Summary

• Fusion Summer Limited and CHEE Choon Wee jointly filed a Schedule 13D, disclosing their beneficial ownership in Helius Medical Technologies, Inc.
• Fusion Summer Limited acquired 6,830,402 shares of Helius Medical Technologies' Class A Common Stock.
• This acquisition represents 17.0% of the outstanding Class A Common Stock.
• The aggregate purchase price for these shares was approximately $47.0 million, funded by Fusion Summer's personal funds.
• The transaction closed on September 18, 2025, as part of a private placement financing (PIPE Transaction).
• Mr. CHEE Choon Wee, the ultimate controlling person of Fusion Summer, was appointed Executive Chairman of Helius Medical Technologies' board of directors, effective upon the closing of the transaction.
• The percentage of beneficial ownership is calculated based on 40,295,612 shares outstanding as of September 24, 2025.

Sentiment

Score: 7

Explanation: The significant investment by a new major shareholder, coupled with the appointment of the investor's controlling person as Executive Chairman, suggests a strong vote of confidence and potential for strategic direction, which is generally positive for the company.

Positives

• A significant investment of approximately $47.0 million by Fusion Summer Limited, strengthening the company's capital base through a private placement.
• The appointment of Mr. CHEE Choon Wee, the controlling person of the investing entity, as Executive Chairman of the board, indicating strong commitment and potential for strategic alignment and oversight.

Negatives

• No explicit negatives are stated in this ownership disclosure filing.

Risks

• The Reporting Persons may acquire additional shares or other securities of the Issuer in the future.
• The Reporting Persons may dispose of any or all of their securities.
• The Reporting Persons may engage in hedging or other transactions with respect to the securities.
• The Reporting Persons may engage in discussions with management, the Board, other stockholders, or take other actions to propose changes in the business, operations, governance, or capitalization of the Issuer, which could introduce uncertainty regarding future strategic direction.

Future Outlook

The Reporting Persons acquired the securities for investment purposes and intend to continuously review their investment. They may, in the future, acquire additional securities, dispose of existing securities, engage in hedging, or discuss and propose changes in the Issuer's business, operations, governance, or capitalization, depending on various factors including the Issuer's financial position, strategic direction, market conditions, and other investment opportunities.

Management Comments

• Mr. CHEE Choon Wee's present principal occupation is serving as the Executive Chairman of the Issuer's board of directors.

Industry Context

This filing primarily details a significant ownership stake acquisition and a related board appointment for Helius Medical Technologies, Inc. It does not provide information to analyze broader industry trends or competitors.

Management Changes

Corporate Governance

Legal Proceedings

• None of the Reporting Persons have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) during the last five years.
• None of the Reporting Persons were a party to a civil proceeding of a judicial or administrative body of competent jurisdiction that resulted in a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws during the last five years.

Related Party Transactions

• Fusion Summer Limited, controlled by Mr. CHEE Choon Wee, acquired 6,830,402 shares of Common Stock for approximately $47.0 million.
• Mr. CHEE Choon Wee was appointed Executive Chairman of the Issuer's board of directors in connection with this transaction, establishing a direct relationship between the investor and company management.

Stakeholder Impact

• Shareholders: Introduction of a new significant shareholder (17.0% stake) and a new Executive Chairman, potentially leading to changes in strategic direction, governance, and capital allocation.
• Management: New Executive Chairman will influence leadership and strategic decisions.
• Company: Strengthened capital base through the PIPE transaction.

Next Steps

• Reporting Persons may acquire additional shares or other securities of the Issuer.
• Reporting Persons may dispose of any or all of their securities.
• Reporting Persons may engage in hedging or other transactions with respect to the securities.
• Reporting Persons may engage in discussions with management, the Board, other stockholders, or take other actions to propose changes in the business, operations, governance, or capitalization of the Issuer.

Key Dates

Recommendation

The filing indicates a significant new investment and the appointment of a major investor's representative as Executive Chairman, which could be a positive catalyst for Helius Medical Technologies. However, without further financial performance details or explicit strategic plans, a 'hold' recommendation is prudent. This allows investors to observe the impact of this new leadership and investment. The potential for future changes in business, operations, governance, or capitalization also introduces an element of uncertainty that warrants careful monitoring.

Keywords

Helius Medical Technologies, Fusion Summer Limited, CHEE Choon Wee, Schedule 13D, beneficial ownership, private placement, PIPE transaction, executive chairman, investment, corporate governance